Pharmaceutical Major, Lupin has announced the acquisition of worldwide rights for the intra-nasal steroid (INS) product, AllerNaze (trimcinolone acetonide USP) Nasal Spray, 50mcg from Collegium Pharmaceutical Inc.

With the latest announcement, the United States will become the first market in which Lupin will launch the product. The domestic pharmaceutical firm expects to expand its US sales force as its launches AllerNaze building on its presence in pediatrics and expanding into other key specialties such as allergy/immunology and otolaryngology.

It should be noted that US Food and Drug Administration (FDA) has already approved AllerNaze Nasal Spray, 50mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve years of age and older.

The shares of Lupin were trading at Rs 820 on BSE. The scrip had made 52-week-high and low of Rs 905 and Rs 518 respectively.